Companies from across the supplement supply chain advocate for a transparent industry and empower consumers to take control of their health. We tell the supplement industry’s story through content, research and education-based events.

Supplement industry news and updates – May 2022

Inside the Bottle brings you the latest supplement industry news in this monthly roundup.

June 1, 2022

2 Min Read
ITB21_Newsletter_1540x800_1.jpg

Signs of inflation showing up in vitamins and supplements — article

Inflation is on everyone’s minds. From consumers to brands, the impacts of inflation are hitting every industry, especially supplements. SPINS data confirms this, with multiple subcategories within supplements seeing significant price increases. Learn more in this article.

Exploring the CBD gummy revolution ­– article

The popularity of gummies as a delivery format for dietary supplements has exploded in recent years, and nowhere is this more apparent than in CBD. But there are often big differences in quality between brands that offer CBD gummies, and companies like Charlotte’s Web that are fully organic and vertically integrated offer the best of the best. Learn more here.

NBJ analysis: Supplement brands innovate with new strategies in brick and mortar as online shopping soars – article

Brick-and-mortar shops suffered during the pandemic, but supplement brands continue to partner with them and develop new ways to train staff and engage customers. Read more in this article. Also, find more in-depth business analysis like this in Nutrition Business Journal.

Dietary supplement trade groups criticize MPL language in Senate bill – article

The formal introduction of a bill Friday in the U.S. Senate that would require listing of dietary supplement products with FDA drew objections from industry trade associations, including those who have generally supported the concept. See why there was so much opposition in this article.

FDA Commissioner Califf on CBD: ‘I’m committed to do something about this’ – article

FDA Commissioner Dr. Robert Califf stated that he’s committed to moving forward on a pathway for CBD during a May 19th hearing held by a subcommittee of the House Committee on Appropriations. The issue, however, is that the FDA doesn’t have the current authorities to move move forward and will require collaboration with lawmakers on Capitol Hill. Read more here.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like